160 related articles for article (PubMed ID: 38132386)
21. Underlying liver disease influences volumetric changes in the spared hemiliver after selective internal radiation therapy with 90Y in patients with hepatocellular carcinoma.
Teo JY; Goh BK; Cheah FK; Allen JC; Lo RH; Ng DC; Goh AS; Khor AY; Sim HS; Ng JJ; Chow PK
J Dig Dis; 2014 Aug; 15(8):444-50. PubMed ID: 24828952
[TBL] [Abstract][Full Text] [Related]
22. Combining Selective Internal Radiation Therapy with Immunotherapy in Treating Hepatocellular Carcinoma and Hepatic Colorectal Metastases: A Systematic Review.
Ramdhani K; Smits MLJ; Lam MGEH; Braat AJAT
Cancer Biother Radiopharm; 2023 May; 38(4):216-224. PubMed ID: 36595357
[No Abstract] [Full Text] [Related]
23. Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation.
Lo EC; N Rucker A; Federle MP
Semin Radiat Oncol; 2018 Oct; 28(4):267-276. PubMed ID: 30309637
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
Pitton MB; Kloeckner R; Ruckes C; Wirth GM; Eichhorn W; Wörns MA; Weinmann A; Schreckenberger M; Galle PR; Otto G; Dueber C
Cardiovasc Intervent Radiol; 2015 Apr; 38(2):352-60. PubMed ID: 25373796
[TBL] [Abstract][Full Text] [Related]
25. Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages.
Moctezuma-Velazquez C; Montano-Loza AJ; Meza-Junco J; Burak K; Ma M; Bain VG; Kneteman N; Sarlieve P; Owen RJ
Dig Dis Sci; 2021 Mar; 66(3):899-911. PubMed ID: 32281043
[TBL] [Abstract][Full Text] [Related]
26. Catheter-Directed Computed Tomography Hepatic Angiography for Yttrium-90 Selective Internal Radiotherapy of Hepatocellular Carcinoma Reduces Prophylactic Embolization of Extrahepatic Vessels.
Goh WXT; Leong S; Too CW; Cheng LT; Saffari SE; Lee RZ; Ng STS; Lo RHG; Tay KH; Chan SXJM; Gogna A; Irani FG; Venkatanarasimha N; Loke KSH; Chow PKH; Ng DCE; Urlings TAJ; Patel A; Damodharan K; Toh LHW; Tan BS
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):478-487. PubMed ID: 31705243
[TBL] [Abstract][Full Text] [Related]
27. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
[TBL] [Abstract][Full Text] [Related]
28. Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes.
Mafeld S; Littler P; Hayhurst H; Manas D; Jackson R; Moir J; French J
J Gastrointest Cancer; 2020 Mar; 51(1):152-158. PubMed ID: 30911980
[TBL] [Abstract][Full Text] [Related]
29. Repeated SBRT for in- and out-of-field recurrences in the liver.
Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
[TBL] [Abstract][Full Text] [Related]
30. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization.
Weng Z; Ertle J; Zheng S; Lauenstein T; Mueller S; Bockisch A; Gerken G; Yang D; Schlaak JF
PLoS One; 2013; 8(12):e82225. PubMed ID: 24367506
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
Zeng H; Zhou C; Chen X; Hu L; Su K; Guo L; Han Y
Clin Exp Med; 2023 Oct; 23(6):2141-2150. PubMed ID: 36737488
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
33. Selective internal radiation therapy with yttrium-90 resin microspheres followed by anatomical hepatectomy: A potential curative strategy in advanced hepatocellular carcinoma.
Feng X; Zhang L; Niu H; Zhang H; Yang L; Wen Y; Chen SY; Shi Y; He Z; Yu L; Wang Y; Huang X; Wang Z; Qin M; Wen X; Zhang Z; Song J; Zheng Z; Yin H; Zhang H; Ma L; Wei J; Wu X; Zhang L; Zhao Y; Lu Q; Xiao H; Liu T; Fang P; Wei L; Gandhi RT; Dong J
Asia Pac J Clin Oncol; 2024 Apr; 20(2):319-322. PubMed ID: 36658669
[TBL] [Abstract][Full Text] [Related]
34. Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England.
Pollock RF; Shergill S; Carion PL; von Oppen N; Agirrezabal I; Brennan VK
Adv Ther; 2023 Jan; 40(1):294-309. PubMed ID: 36318388
[TBL] [Abstract][Full Text] [Related]
35. Mortality after liver surgery in Germany.
Filmann N; Walter D; Schadde E; Bruns C; Keck T; Lang H; Oldhafer K; Schlitt HJ; Schön MR; Herrmann E; Bechstein WO; Schnitzbauer AA
Br J Surg; 2019 Oct; 106(11):1523-1529. PubMed ID: 31339558
[TBL] [Abstract][Full Text] [Related]
36. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
Pollock RF; Colaone F; Guardiola L; Shergill S; Brennan VK
J Med Econ; 2020 Jun; 23(6):593-602. PubMed ID: 32067534
[No Abstract] [Full Text] [Related]
37. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of one month imaging following selective internal radiation therapy.
Young S; Taylor A; Golzarian J; Flanagan S; D'Souza D; Sanghvi T
Diagn Interv Imaging; 2019 Jan; 100(1):39-46. PubMed ID: 30082184
[TBL] [Abstract][Full Text] [Related]
39. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma.
Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869
[TBL] [Abstract][Full Text] [Related]
40. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
